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Abstract
Background: Prokineticin 2 (PK2) expression is upregulated in mice with collagen-induced arthritis (CIA), an animal
model of rheumatoid arthritis. The purpose of our study was to investigate the effects of PK2 inhibition on CIA.
Methods: PK2, prokineticin receptor (PKR) 1, and PKR2 mRNA transcripts in the joints of CIA mice were measured
by real-time PCR on Days 21, 28, and 35 (n = 15/day). Localization of PKR1 and PKR2 proteins was examined
immunohistochemically. PKRA7, a PK2 antagonist, was administered intraperitoneally for 2 weeks to CIA mice,
and the severity of arthritis was compared between treated (n = 12) and untreated (n = 12) mice. The gene
expression levels of inflammatory cytokines IL-1β, IL-6, TNF-α, and VEGF were also measured by real-time PCR
and compared between treated (n = 6) and untreated (n = 6) CIA mice. The data was statistically analyzed, and
P values of less than 0.05 were considered significant.
Results: In the thickened synovial membrane, PKR1 protein was expressed in infiltrating neutrophils, while PKR2
expression was found in macrophage-like mononuclear cells. PK2 gene expression was significantly more pronounced
on Days 28 and 35 than on Day 21 (2.15 and 2.03 versus 1.00, P = 0.0311 and 0.0247; Dunn’s multiple comparison).
PKR2 gene expression levels were significantly higher on Days 28 and 35 compared to Day 21 (25.4 and 39.3 versus 1.0,
P = 0.002 and < 0.0001; Dunn’s multiple comparison). Administration of PKRA7 suppressed the severity of arthritis
(P < 0.001; two-way analysis of variance). A gene expression analysis of inflammatory cytokines revealed significantly
reduced IL-1β and lL-6 expression in the joints of PKRA7-treated mice compared to untreated mice (0.1 versus 1.0,
P = 0.0043 and 0.04 versus 1.0, P = 0.0022, respectively; Mann-Whitney test).
Conclusions: PK2 inhibition suppressed arthritis in mice with CIA.
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Background
Prokineticin 2 (PK2) is a large-class secreted peptide
containing a five-disulfide-bridged motif called a colipase
fold [1]. Two types of G-protein-coupled receptors, pro-
kineticin receptor 1 (PKR1) and prokineticin receptor 2
(PKR2), have been identified as the target of PK2. PK2
and its receptors are expressed in various tissues, e.g.,
the testis, skin, lung, intestine, ovary and the central
nervous system as well as circulating neutrophils,
macrophages and lymphocytes [2–5], and involved in
diverse physiological functions such as angiogenesis,
neurogenesis, circadian rhythm, and pain thresholds
[1, 6–9]. Abnormalities in PK2-PKR1/2 signaling have
been associated with various human diseases, including
polycystic ovarian syndrome, myocardial infarction, colo-
rectal cancer, and Kallmann syndrome [10–12]. In light of
the fact that angiogenesis plays an important role in the
pathogenesis of rheumatoid arthritis [13, 14], we previ-
ously investigated PK2 expression in mice with collagen-
induced arthritis (CIA), the animal model of rheumatoid
arthritis, and reported that PK2 gene expression was sig-
nificantly elevated in the joints of CIA mice and correlated
with the severity of the arthritis [15]. More recently, such
upregulation of PK2 has been reported also in a rat testitis
model [16], a mouse model of inflammatory colitis [17],
and a mouse model with autoimmune encephalomyelitis
[18]. In in vitro studies, PK2 has been shown to induce
proinflammatory cytokine production by macrophages
and splenocytes [2, 3]. Taken together, these findings point
to PK2’s role in various inflammatory diseases.
PKRA7 is a small molecular inhibitor developed by
Curtis et al. by substitution of alanine with methionine
and addition of methionine at the N-terminus of PK2;
the mutated peptide mimics PK2 and competitively
blocks PK2-PKR1/2 interactions [19] (Fig. 1). The
researchers showed that this molecule inhibits angiogen-
esis and macrophage infiltration in mice transplanted
with glioblastoma and pancreatic cancer, respectively
[19]. The primary goal of our study was to investigate




All animal experiments were approved by the Institutional
Animal Care and Use Committee of the Jikei University,
Tokyo, Japan. Five-week-old DBA/1 J mice (n = 69) were
purchased from Sankyo Labo Service (Tokyo, Japan) and
immunized intradermally at the dorsal root of the tail with
bovine type II collagen (200 μg/mouse; Collagen Research
Center, Tokyo, Japan) emulsified in Freund’s complete
adjuvant (Becton Dickinson and Company, NJ, USA)
(Day 0). On Day 21, a booster injection of bovine
type II collagen emulsified in Freund’s incomplete
adjuvant (Becton Dickinson and Company) was
administered in the same manner. The severity of
arthritis was evaluated by a clinical rheumatologist (study
co-author KO), who was blinded to the study groups, and
expressed as the sum of the scores for all four limbs as
assessed on the following scale: 0, normal; 1, swelling of
digits alone or mild swelling of wrist and ankle joints; 2,
clear swelling of wrist and ankle joints; and 3, severe
swelling of wrist and ankle joints.
Fig. 1 PKRA7 as an antagonist of PK2. PK2 binds to PKR1 and PKR2 receptors and regulates various physiological processes, including angiogenesis,
chemotaxis, immune polarization, and circadian rhythm. PKRA7 also binds to PKR1 and PKR2 and competitively blocks the binding of PK2
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Gene expression analysis of joints
CIA mice were sacrificed under isoflurane anesthesia.
The forelimbs and hindlimbs were amputated 5 mm
proximal to the wrist and ankle joints, and RNA was
extracted using an RNeasy Lipid Tissue Mini Kit
(Qiagen, Tokyo, Japan). Real-time PCR was performed
on an Applied Biosystems StepOne Plus Real-Time
PCR System (Thermo Fisher Scientific, MA, USA) using
TaqMan probes and primers (Thermo Fisher Scientific)
for PK2 (Mm00450080_m1), PKR1 (Mm01204733_m1),
PKR2 (Mm00769571_m1), IL-1 (Mm01336189_m1), IL-6
(Mm00446190_m1), TNF-α (Mm00443258_m1), VEGF
(Mm01281449_m1), and β-actin (Mm00607939_s1). Gene
expression levels were analyzed by the ΔΔCT method
using β-actin as a reference gene.
The gene expression levels of PK2, PKR1, and PKR2
were analyzed for the CIA mice sacrificed on Days 21,
28, and 35. The gene expression levels on Days 28 and
35 were expressed relative to the arbitrary assigned value
on Day 21 (=1.0). The experiment was repeated 3 times
for each group of five mice (5 mice × 3 days × 3 repeti-
tions = 45 mice). The correlation between arthritis scores
and PK2, PKR1, and PKR2 gene expression levels was
analyzed for all 45 mice. Separately, cytokine gene ex-
pression levels were analyzed for the PKRA7-treated and
-untreated mice (n = 6 each) sacrificed on Day 35 and
were expressed relative to the values obtained for un-
treated mice.
PKR1 and PKR2 protein analysis
For immunohistochemical staining of PKR1, isolated
joints on Day 35 were perfusion-fixed, decalcified, and
embedded in optimal cutting temperature compound
(Sakura Finetek, CA, USA) for frozen sectioning (at a
thickness of 7 μm). For PKR2 immunostaining, the
tissues were embedded in optimal cutting temperature
compound without fixation or decalcification and cryo-
sectioned. Endogenous peroxidase was inactivated with a
peroxidase blocking reagent (Dako, Glostrup, Denmark).
Sections were incubated with a primary antibody, either
rabbit anti-mouse PKR1 antibody (Covalab, Villeurbanne,
France) or rabbit anti-mouse PKR2 antibody (Covalab),
and then with a secondary antibody (Simple Stain Rabbit
Max PO; Nichirei Bioscience, Tokyo, Japan). Simple
Stain DAB Solution (Nichirei Bioscience) was used for
visualization of the secondary antibody. The sections
were then counterstained with hematoxylin and exam-
ined under a light microscope (Axio Imager A1, Carl
Zeiss, Göttingen, Germany).
Administration of PKRA7
DMSO was used as a vehicle. Prior to administration,
PKRA7 in DMSO was diluted with PBS to adjust the
concentration of DMSO to 5 %. CIA mice received
either 15 mg/kg/day of PKRA7 or 5 % DMSO (control)
for 2 weeks from Day 21. The experiment was repeated
twice in groups of 6 mice (n = 12). On Day 35, the mice
were sacrificed and their limbs amputated. Isolated
joints were fixed, decalcified, and embedded in paraffin,
and the blocks were sectioned into slices at a thickness
of 4 μm. Sections were stained with hematoxylin and
eosin and examined under an Axio Imager A1 micro-
scope. The gene expression levels of inflammatory cyto-
kines IL-1β, IL-6, TNF-α, and VEGF were also measured
by real-time PCR and compared between PKRA7-treated
(n = 6) and -untreated (n = 6) CIA mice on Day 35.
Statistical analysis
The gene expression levels of PK2, PKR1, and PKR2 on
Days 21, 28, and 35 were analyzed by a Kruskal-Wallis
test with a Dunn’s multiple comparison test post hoc.
Spearman’s rank correlation coefficients were used to
examine the correlation between arthritis scores and rela-
tive gene expression. Arthritis scores for untreated and
treated mice were compared by two-way analysis of vari-
ance with a Sidak’s multiple comparison test post hoc. Cyto-
kine gene expression was analyzed by a Mann-Whitney
test. All results were expressed as mean values ± SEM.
Results
Changes in arthritis scores in CIA mice are shown in
Fig. 2a. Scores peaked on Day 33 and decreased there-
after. Real-time PCR results showed that PK2 gene ex-
pression was significantly more pronounced on Days 28
and 35 than on Day 21 (Fig. 2b; 2.15 and 2.03 versus
1.00, P = 0.0311 and P = 0.0247, respectively). PKR1 gene
expression levels were similar on all days (Fig. 2c), while
PKR2 gene expression levels were significantly higher on
Days 28 and 35 compared to Day 21 (Fig. 2d; 25.4 and
39.3 versus 1.0, P = 0.002 and P ≤ 0.0001, respectively).
The Spearman’s rank correlation test revealed a signifi-
cant correlation between arthritis scores and relative
PK2 gene expression levels with a correlation coefficient
of 0.60 (Fig. 3a, P < 0.001). Arthritis scores were not cor-
related with PKR1 gene expression levels (Fig. 3b) but
were significantly correlated with PKR2 gene expression
levels (Fig. 3c, P < 0.0001).
Immunohistochemical staining of PKR1 and PKR2
proteins showed that PKR1-positive cells were predom-
inantly neutrophils infiltrating in the synovial membrane
(Fig. 4a). PKR2-positive cells were also found in the
synovium but associated with macrophage-like mono-
nuclear cells (Fig. 4b).
Daily intraperitoneal administration of the PK2 antag-
onist PKRA7 to CIA mice before the onset of arthritis
from Day 21 resulted in significantly lower arthritis
scores in treated mice compared to control CIA mice on
Days 28, 31, 33, and 35 (Fig. 5a; P = 0.0104, P = 0.0018,
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P < 0.001 and P < 0.001, respectively). The mean arthritis
score on Day 35 was 4.67 for the control group versus
1.75 for the PKRA7-treated mice. Histological evaluation
of the synovium of the ankle joints showed less extensive
inflammatory cell infiltration and synovial thickening in
treated mice than in control mice on Day 35 (Fig. 5b, c).
The gene expression analysis of inflammatory cytokine
on Day 35 revealed significantly lower IL-1β and 1 L-6
expression levels in the joints of PKRA7-treated mice
compared to control mice (Fig. 6a, b; P = 0.0043 and
P = 0.0022, respectively). TNF-α gene expression levels
were also lower in PKRA7-treated mice, albeit with-
out statistical significance (Fig. 6c). There was no sig-
nificant difference in VEGF gene expression between
the two groups (Fig. 6d).
Discussion
In the present study, we demonstrated that PKR1 pro-
tein was expressed in infiltrating neutrophils, while
PKR2 protein was present in macrophage-like mono-
nuclear cells in the synovial membrane of CIA mice. We
also found that PK2 and PKR2 gene expression levels
were elevated in the CIA joints and that administration
of PKRA7 suppressed the severity of arthritis.
PKR1 is expressed in neutrophils, macrophages, and
lymphocytes [2, 3, 5]. In inflamed joints, therefore, PKR1
expression is likely found in those blood cells infiltrating
the synovial membrane. To demonstrate this fact, we
performed immunohistochemical staining of PKR1 pro-
tein using a well-established mouse model of rheumatoid
arthritis. We found that PKR1 was expressed in neutro-
phils in the synovial membrane. Although there was no
increase in PKR1 gene expression, the gene expression
levels of its ligand PK2 were elevated, indicating that
PK2-PKR1 signaling was likely enhanced in those
synovial neutrophils. In the light of the diverse roles of
neutrophils in the development of rheumatoid arthritis
[20], these results are encouraging for future studies
focusing on the exact mechanism of the PK2-PKR1
pathway in the pathogenesis of arthritis in this model.
Like PKR1, PKR2 is expressed in neutrophils, macro-
phages, and lymphocytes in the blood [2, 3, 5]. We
found that PKR2 protein was present in macrophage-
like cells in the synovial membrane of CIA mice and
that, unlike PKR1, PKR2 gene expression was more pro-
nounced in inflamed joints. Furthermore, the level of
PKR2 gene expression was significantly correlated with
the severity of the arthritis.
To investigate the effects of PK2 inhibition on arth-
ritis, we used the PK2 antagonist PKRA7. PKRA7 has
been shown to decrease tumor size by inhibiting angio-
genesis and macrophage infiltration when administered
Fig. 2 Changes in arthritis scores and PK2, PKR1, and PKR2 gene expression before and after the onset of arthritis. Arthritis was experimentally
induced with a collagen injection on Day 21. a The severity of arthritis peaked on Day 33 and decreased thereafter. b PK2 gene expression in the
joints was more elevated on Days 28 and 35 than on Day 21. c There was no significant change in PKR1 gene expression levels before and after
the onset of arthritis. d PKR2 gene expression was significantly more pronounced on Days 28 and 35 than on Day 21. Values are relative to the
arbitrarily assigned value of 1.0 for Day 21 and are given as means ± SEM. P values by Dunn’s multiple comparison
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to mouse models of glioblastoma and pancreatic cancer,
respectively, at a dose rate of 20 mg/kg/day for 14 days
[19]. Based on this report, we administered 15 mg/kg/
day of PKRA7 to CIA mice for 14 days from Day 21 and
found that PKRA7 significantly suppressed the severity
of arthritis. Because PKRA7 can bind to both PKR1 and
PKR2 [19], the observed effect was likely the result of in-
hibition of both of the PK2-PKR1 and PK2-PKR2 path-
ways, possibly via suppression of neutrophil activation in
the former and macrophage infiltration in the latter. In
rheumatoid arthritis, macrophages infiltrate the synovial
membrane and produce IL-1, IL-6, TNF-α, and other in-
flammatory cytokines [21]. In our study, administration
of PKRA7 reduced IL-1 and IL-6 expression significantly
as well as TNF-α gene expression levels to a lesser ex-
tent. These results suggest that PKRA7 may suppress
the severity of arthritis by inhibiting PK2-PKR2 signaling
in macrophages.
We previously proposed the possible role of PK2 in
angiogenesis in arthritis based on elevated VEGF mRNA
levels in CIA mice [15]. Indeed, PKRA7 has been shown
to suppress angiogenesis, leading to tumor shrinkage in
nude mice implanted with glioblastoma cells [19]. Unex-
pectedly, however, PKRA7 did not affect VEGF gene ex-
pression in our study. More study is necessary in order
to understand the direct role of PK2 in angiogenesis.
Fig. 4 Immunostaining of PKR1 and PKR2 proteins in synovial tissue. Brown staining indicates PKR1- or PKR2-positive cells. a Neutrophils infiltrat-
ing in the synovium membrane of CIA mice were positive for PKR1 (400×). b PKR2-positive cells were macrophage-like cells (400×)
Fig. 3 Correlation between arthritis scores and PK2, PKR1, and PKR2 gene expression. Severity scores were significantly correlated with a PK2 and
c PKR2 gene expression levels but not with b PKR1 gene expression based on Spearman’s rank correlation coefficients (r). Data was obtained
from mice sacrificed on Days 21, 28, and 35
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Fig. 6 Comparison of cytokine gene expression in the joints of PKRA7-treated and untreated CIA mice on Day 35. a IL-1 gene expression was
significantly less pronounced in PKRA7-treated mice (P = 0.0022). b IL-6 gene expression was also significantly reduced by PKRA7 (P = 0.0043).
c TNF-α levels were numerically lower for PKRA7-treated mice but did not differ in a statistically significant manner from values for control mice.
d VEGF gene expression was similar without regard to PKRA7 treatment. P values by Mann-Whitney test
Fig. 5 Effects of the PK2 antagonist PKRA7. a Arthritis scores were significantly lower in PKRA7-treated mice compared to control mice. P values
by Sidak’s multiple comparison. b Hematoxylin and eosin staining of the ankle joint synovial membrane of control CIA mice (100×) on Day 35.
c Hematoxylin and eosin staining of the ankle joint synovial membrane of PKRA7-treated CIA mice (100×) on Day 35. Note milder inflammatory
cell infiltration and synovial thickening
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Since PK2 is a multifunctional protein that is likely
involved in various processes of arthritis, a better under-
standing of these functions would be promising for the
development of successful therapies for arthritis.
Our study has several limitations. First, we did not ad-
dress the mechanism by which PKRA7 suppressed the se-
verity of arthritis. Potential consequences of the inhibition
of PK2-PKR1/2 signaling include alterations in immuno-
modulatory, inflammatory, and angiogenetic processes.
Secondly, PK2, PKR1, and PKR2 expression has yet to be
evaluated in human rheumatoid arthritis patients. Lastly,
administration of PKRA7 to human patients may cause
various side effects affecting pain thresholds, mental sta-
tus, and sleep, as PK2 has diverse physiological roles. All
of these questions are left to be answered by future study.
Conclusions
PKRA7 suppressed the severity of arthritis and inflam-
matory cytokines in mice with collagen-induced arthritis.
These results are encouraging for a possible application
of the PK2 inhibitor as a new approach in the treatment
of arthritis.
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